July and August have brought a steady beat of private financings for young medtech companies, with several deals supporting new technologies to treat heart conditions.
Heart devices pace medtech’s summer funding flows Read More »
Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip insurance. This is not the first time Novo has partnered with a pharmacy to offer the blockbuster drugs.
Novo Teams Up With GoodRx for Lower-Price GLP-1s, Giving DTC Another Shot Read More »
Waltham, Massachusetts–based Skyhawk Therapeuticshas been collecting collaborations with larger companies in spades since launching in 2018.
Merck KGaA Drops up to $2B in Skyhawk Collab for RNA-Targeting Tech Read More »
Kriya is advancing a host of gene therapies for a wide variety of chronic diseases, including geographic atrophy, trigeminal neuralgia and type 1 diabetes.
Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain episodes in patients with sickle cell disease over the 48-week treatment period.
Pfizer’s $5.4B GBT Bet Disappoints Again as Sickle Cell Therapy Fails in Phase III Read More »
The telehealth firm is targeting international expansion as part of its strategic revamp.
Teladoc acquires Australian virtual care firm Telecare Read More »
The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according to analysts at BMO Capital Markets.
In Phase III studies, Tonmya showed significantly superior analgesic effects in fibromyalgia patients versus placebo. The sublingual pill also led to better clinical outcomes.
Tonix Wins Approval For First New Fibromyalgia Drug in Over 15 Years Read More »
More star ratings changes are coming – and your actions this summer are critical for Stars success.
Why this summer is make-or-break for star ratings Read More »
Noticias de la actualidad astronómica y astronáutica del 18 de agosto de 2025. …
